IL156872A0 - 6-substituted pyrido-pyrimidines - Google Patents

6-substituted pyrido-pyrimidines

Info

Publication number
IL156872A0
IL156872A0 IL15687202A IL15687202A IL156872A0 IL 156872 A0 IL156872 A0 IL 156872A0 IL 15687202 A IL15687202 A IL 15687202A IL 15687202 A IL15687202 A IL 15687202A IL 156872 A0 IL156872 A0 IL 156872A0
Authority
IL
Israel
Prior art keywords
pyrimidines
substituted pyrido
pyrido
substituted
Prior art date
Application number
IL15687202A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL156872A0 publication Critical patent/IL156872A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL15687202A 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines IL156872A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Publications (1)

Publication Number Publication Date
IL156872A0 true IL156872A0 (en) 2004-02-08

Family

ID=26953040

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15687202A IL156872A0 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines
IL156872A IL156872A (en) 2001-02-12 2003-07-10 Pyrido – pyrimidines 6 – transformed

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156872A IL156872A (en) 2001-02-12 2003-07-10 Pyrido – pyrimidines 6 – transformed

Country Status (32)

Country Link
US (3) US6696566B2 (xx)
EP (1) EP1361880B1 (xx)
JP (1) JP4064818B2 (xx)
KR (1) KR100639772B1 (xx)
CN (1) CN100376571C (xx)
AR (1) AR035854A1 (xx)
AT (1) ATE305303T1 (xx)
AU (1) AU2002256615B2 (xx)
BR (1) BRPI0207172B8 (xx)
CA (1) CA2434834C (xx)
CZ (1) CZ20032416A3 (xx)
DE (1) DE60206363T2 (xx)
DK (1) DK1361880T3 (xx)
ES (1) ES2249574T3 (xx)
HK (1) HK1066170A1 (xx)
HR (1) HRP20030624B1 (xx)
HU (1) HU229604B1 (xx)
IL (2) IL156872A0 (xx)
JO (1) JO2410B1 (xx)
MA (1) MA26993A1 (xx)
MX (1) MXPA03007166A (xx)
MY (1) MY131518A (xx)
NO (1) NO326133B1 (xx)
NZ (1) NZ526961A (xx)
PA (1) PA8539201A1 (xx)
PE (1) PE20020976A1 (xx)
PL (1) PL366918A1 (xx)
RU (1) RU2269527C2 (xx)
SK (1) SK11322003A3 (xx)
WO (1) WO2002064594A2 (xx)
YU (1) YU63703A (xx)
ZA (1) ZA200305938B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
AU2003215675B2 (en) 2002-04-03 2007-07-12 F. Hoffmann-La Roche Ag Imidazo fused compounds
RU2324695C2 (ru) * 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
CN1774250A (zh) * 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6－(苯氧基)－吡啶并[3,4－d]嘧啶－2－基)－胺衍生物
EP1685131B1 (en) * 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US20090036472A1 (en) * 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
DE602006010564D1 (de) * 2005-07-21 2009-12-31 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
PL2099797T3 (pl) * 2005-08-09 2011-03-31 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
AU2008248296B2 (en) 2007-05-07 2011-12-01 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use
CN101679211A (zh) 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
WO2009117156A1 (en) 2008-03-21 2009-09-24 Amgen Inc. Pyrazolo-pyrazinone compounds and methods of use thereof
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010046273A2 (en) * 2008-10-22 2010-04-29 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
WO2011044535A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
UA123914C2 (uk) 2016-06-08 2021-06-23 Суппорт-Венче Гмбх Фармацевтичні комбінації для лікування раку
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
AU2017313296A1 (en) * 2016-08-17 2019-02-14 Support-Venture Gmbh Method of preventing or treating hearing loss
WO2018132550A1 (en) 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
AU2018248578A1 (en) 2017-04-04 2019-10-17 Kinarus Ag Methods of preventing or treating ophthalmic diseases
JP2021501123A (ja) * 2017-08-31 2021-01-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒおよび／またはｈｅｒ２の阻害剤ならびに使用方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US20210261547A1 (en) * 2018-06-27 2021-08-26 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
AU2019300135A1 (en) 2018-07-13 2021-01-28 Kinarus Ag Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US20230263803A1 (en) 2020-08-11 2023-08-24 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
AU7108398A (en) 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7－三取代的－4－氨基吡啶并[2,3－d]嘧啶化合物
PL344248A1 (en) 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
MXPA02008535A (es) * 2000-03-06 2002-12-13 Warner Lambert Co Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa.
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner

Also Published As

Publication number Publication date
KR20040018254A (ko) 2004-03-02
CN1503672A (zh) 2004-06-09
MXPA03007166A (es) 2003-11-18
CA2434834C (en) 2010-09-14
ATE305303T1 (de) 2005-10-15
US6696566B2 (en) 2004-02-24
BRPI0207172B1 (pt) 2019-04-09
EP1361880A2 (en) 2003-11-19
AR035854A1 (es) 2004-07-21
JP4064818B2 (ja) 2008-03-19
YU63703A (sh) 2006-05-25
WO2002064594A3 (en) 2003-01-09
CN100376571C (zh) 2008-03-26
DK1361880T3 (da) 2006-01-23
US7169794B2 (en) 2007-01-30
WO2002064594A2 (en) 2002-08-22
HRP20030624B1 (en) 2007-03-31
US20070135458A1 (en) 2007-06-14
RU2003125887A (ru) 2005-03-20
RU2269527C2 (ru) 2006-02-10
MY131518A (en) 2007-08-30
NO20033540L (no) 2003-08-11
AU2002256615B2 (en) 2007-09-13
ES2249574T3 (es) 2006-04-01
IL156872A (en) 2009-07-20
HUP0303458A2 (hu) 2004-01-28
CZ20032416A3 (cs) 2004-07-14
NO326133B1 (no) 2008-10-06
NO20033540D0 (no) 2003-08-11
US20040116698A1 (en) 2004-06-17
SK11322003A3 (en) 2004-10-05
HK1066170A1 (en) 2005-03-18
PA8539201A1 (es) 2004-08-31
PL366918A1 (en) 2005-02-07
BRPI0207172B8 (pt) 2021-05-25
MA26993A1 (fr) 2004-12-20
PE20020976A1 (es) 2002-10-29
JP2004525896A (ja) 2004-08-26
KR100639772B1 (ko) 2006-10-30
JO2410B1 (en) 2007-06-17
HU229604B1 (en) 2014-02-28
ZA200305938B (en) 2005-01-26
US20030171584A1 (en) 2003-09-11
HRP20030624A2 (en) 2005-06-30
EP1361880B1 (en) 2005-09-28
BR0207172A (pt) 2004-03-30
DE60206363T2 (de) 2006-07-06
NZ526961A (en) 2005-03-24
US7449581B2 (en) 2008-11-11
HUP0303458A3 (en) 2012-12-28
CA2434834A1 (en) 2002-08-22
DE60206363D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
IL156872A0 (en) 6-substituted pyrido-pyrimidines
DE50202400D1 (en) Baw-resonator
DE50201180D1 (en) Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere
DE50209614D1 (en) 2-heteroarylcarbonsäureamide
DE50211022D1 (en) Heteroarylcarbonsäureamide
SI1671949T1 (sl) Substituirani pridinilamini
GB2381204B (en) Putter-heads
DE50202633D1 (en) Ophthalmoskop
PL362643A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AU2002360430A8 (en) 14-methyl-epothilones
PL368050A1 (en) Substituted 4-aminocyclohexanols
DE60107296D1 (en) Kabelverstärkerverbindungsanordnung
DE50206483D1 (en) Displaymodul
DE50203686D1 (en) Substituierte c-furan-2-yl-methylamin- und c-thiophen-2-yl-methylamin-derivate
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
DE50214962D1 (en) Heterocyclylarylsulfonamide
AU2002313943A8 (en) Electromobile
GB0106567D0 (en) Mutuagenesis Technique
PL364601A1 (en) Substituted benzo-nitro-heterocycles
SI1361880T1 (sl) 6-substituirani pirido-pirimidini
AU2001100134A4 (en) Enviro-trap
CA93125S (en) Tilt-latch
CA93647S (en) Fauteuil
CA91502S (en) Bedboard
AU2479P (en) Crackerjack xTriticosecale